SG11202109671WA - Imidazoline derivatives as cxcr4 modulators - Google Patents
Imidazoline derivatives as cxcr4 modulatorsInfo
- Publication number
- SG11202109671WA SG11202109671WA SG11202109671WA SG11202109671WA SG 11202109671W A SG11202109671W A SG 11202109671WA SG 11202109671W A SG11202109671W A SG 11202109671WA SG 11202109671W A SG11202109671W A SG 11202109671WA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- methyl
- imidazol
- thio
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305409 | 2019-03-29 | ||
| PCT/EP2020/058728 WO2020201096A1 (en) | 2019-03-29 | 2020-03-27 | Imidazoline derivatives as cxcr4 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109671WA true SG11202109671WA (en) | 2021-10-28 |
Family
ID=66102603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109671W SG11202109671WA (en) | 2019-03-29 | 2020-03-27 | Imidazoline derivatives as cxcr4 modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144853A1 (https=) |
| EP (1) | EP3947394A1 (https=) |
| JP (1) | JP2022527641A (https=) |
| KR (1) | KR20210146318A (https=) |
| CN (1) | CN113939521A (https=) |
| AU (1) | AU2020255206A1 (https=) |
| BR (1) | BR112021019344A8 (https=) |
| CA (1) | CA3132527A1 (https=) |
| IL (1) | IL286399A (https=) |
| MX (1) | MX2021011599A (https=) |
| SG (1) | SG11202109671WA (https=) |
| WO (1) | WO2020201096A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE565868A (https=) | 1957-03-21 | |||
| DE2348525A1 (de) | 1972-09-28 | 1974-04-11 | Searle & Co | 2- eckige klammer auf 2-(2-methyl-5nitro-1-imidazolyl)-aethyl eckige klammer zu -2-thio-pseudoharnstoffe |
| US4205071A (en) | 1976-05-14 | 1980-05-27 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions having immunosuppressant activity and methods therefor |
| US4349674A (en) | 1978-12-18 | 1982-09-14 | American Home Products Corporation | Quinoalinyl esters of carbamimidothioic acids |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US20040254221A1 (en) | 2001-09-28 | 2004-12-16 | Toru Yamazaki | Novel Nitrogenous Compound and use thereof |
| GB0324498D0 (en) * | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
| CA3027296A1 (en) * | 2016-06-16 | 2017-12-21 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
-
2020
- 2020-03-27 CN CN202080039433.1A patent/CN113939521A/zh active Pending
- 2020-03-27 JP JP2021560358A patent/JP2022527641A/ja active Pending
- 2020-03-27 EP EP20715345.3A patent/EP3947394A1/en active Pending
- 2020-03-27 KR KR1020217032120A patent/KR20210146318A/ko not_active Ceased
- 2020-03-27 WO PCT/EP2020/058728 patent/WO2020201096A1/en not_active Ceased
- 2020-03-27 AU AU2020255206A patent/AU2020255206A1/en not_active Abandoned
- 2020-03-27 BR BR112021019344A patent/BR112021019344A8/pt not_active Application Discontinuation
- 2020-03-27 US US17/599,785 patent/US20220144853A1/en active Pending
- 2020-03-27 SG SG11202109671W patent/SG11202109671WA/en unknown
- 2020-03-27 CA CA3132527A patent/CA3132527A1/en active Pending
- 2020-03-27 MX MX2021011599A patent/MX2021011599A/es unknown
-
2021
- 2021-09-14 IL IL286399A patent/IL286399A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020201096A1 (en) | 2020-10-08 |
| CN113939521A (zh) | 2022-01-14 |
| CA3132527A1 (en) | 2020-10-08 |
| MX2021011599A (es) | 2021-12-10 |
| BR112021019344A8 (pt) | 2022-12-06 |
| IL286399A (en) | 2021-10-31 |
| AU2020255206A1 (en) | 2021-10-14 |
| KR20210146318A (ko) | 2021-12-03 |
| BR112021019344A2 (https=) | 2021-12-14 |
| EP3947394A1 (en) | 2022-02-09 |
| JP2022527641A (ja) | 2022-06-02 |
| US20220144853A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6987843B2 (ja) | Ｐａｄ４の共有結合性阻害剤 | |
| JP6291132B2 (ja) | ブルートンチロシンキナーゼ阻害剤 | |
| CA3121408A1 (en) | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof | |
| KR20210025061A (ko) | 세레블론(crbn)에 대한 리간드 | |
| KR101762981B1 (ko) | 기분 장해 치료제 | |
| JP2022551972A (ja) | Ｐｄ－ｌ１疾患の治療のためのヘテロアリール－ビフェニルアミン | |
| MXPA06001758A (es) | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. | |
| JP2018537535A (ja) | Ｐａｄ４のアザベンゾイミダゾール阻害剤 | |
| KR20200015604A (ko) | C5a 억제제로서의 6-5 융합 고리 | |
| US20210393759A1 (en) | Methods of treating cancer using heteroaryl-biphenyl amide derivatives | |
| US20160024114A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| US20260078103A1 (en) | Isoquinolones as pi3k inhibitors | |
| US20240018125A1 (en) | Cyclic isothiourea derivatives as cxcr4 modulators | |
| US20190127390A1 (en) | Macrocyclic rip2 kinase inhibitors | |
| SG11202109671WA (en) | Imidazoline derivatives as cxcr4 modulators | |
| US20250361239A1 (en) | Protein degraders and uses thereof | |
| AU2014397042A1 (en) | Hydantoin derivative-containing pharmaceutical composition | |
| WO2018187509A1 (en) | Heterocyclic compounds as chemokine receptor modulators | |
| CA3152329C (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| JP7776616B2 (ja) | Ｐｄ－ｌ１相互作用の免疫調節剤としての化合物 | |
| KR20260025059A (ko) | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 | |
| EP3325480A1 (en) | 5-substituted-7-[4-(substituted)benzyl]amino-3-isopropylpyrazolo(4,3-d)pyrimidines as medicaments | |
| CA3138419A1 (en) | Heterocyclic derivatives and use thereof | |
| HK1173144A (en) | Therapeutic agent for mood disorders | |
| HK1173144B (en) | Therapeutic agent for mood disorders |